Should Sanofi recruit Smith & Nephew's French CEO to replace Viehbacher?

Olivier Bohuon, the CEO of artificial hip and knee maker Smith & Nephew ($SNN), may have a leg up over other potential candidates to take the reins of drugmaker Sanofi ($SNY) after the firing of Chris Viehbacher last week. He has experience in pharma and has excelled at Smith & Nephew by moving it into new markets. Most importantly, he is French. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.